Friday, 1 September 2017

Statements of Principles Updates

At the meeting of 2 August 2017 the RMA:

Determined Statements of Principles (SOPs) for:

alcohol use disorder48/201749/2017
rheumatoid arthritis50/201751/2017
These SOPs revoke the SOPs previously determined for these conditions.

Determined New Statements of Principles (SOPs) for:

tooth wear52/201753/2017
popliteal entrapment syndrome54/201755/2017
benign paroxysmal positional vertigo56/201757/2017

Veterans' Entitlements (Statements of Principles—Cumulative Equivalent Dose) Amendment Determination 2017

acoustic neuroma58/201758/2017
acquired cataract58/201758/2017
acute lymphoblastic leukaemia58/201758/2017
acute myeloid leukaemia58/201758/2017
adenocarcinoma of the kidney58/201758/2017
Alzheimer-type dementia58/2017 
angle-closure glaucoma58/201758/2017
aortic stenosis58/201758/2017
atherosclerotic peripheral vascular disease58/201758/2017
benign neoplasm of the eye and adnexa58/201758/2017
carotid arterial disease58/201758/2017
cerebral meningioma58/201758/2017
cerebrovascular accident58/201758/2017
chronic gastritis and chronic gastropathy58/201758/2017
chronic myeloid leukaemia58/201758/2017
chronic pancreatitis58/201758/2017
cirrhosis of the liver58/2017 
erectile dysfunction58/201758/2017
external burn58/201758/2017
fibrosing interstitial lung disease58/201758/2017
gastric ulcer and duodenal ulcer58/201758/2017
Graves' disease58/201758/2017
Hashimoto's thyroiditis58/201758/2017
heart block58/201758/2017
ischaemic heart disease58/201758/2017
malignant neoplasm of the bile duct58/201758/2017
malignant neoplasm of the bladder58/201758/2017
malignant neoplasm of bone and articular cartilage58/201758/2017
malignant neoplasm of the brain58/201758/2017
malignant neoplasm of the breast58/201758/2017
malignant neoplasm of the cerebral meninges58/201758/2017
malignant neoplasm of the colorectum58/201758/2017
malignant neoplasm of the endometrium58/201758/2017
malignant neoplasm of the gallbladder58/201758/2017
malignant neoplasm of the liver58/201758/2017
malignant neoplasm of the lung58/201758/2017
malignant neoplasm of the oesophagus58/201758/2017
malignant neoplasm of the ovary58/201758/2017
malignant neoplasm of the renal pelvis and ureter58/201758/2017
malignant neoplasm of the salivary gland58/201758/2017
malignant neoplasm of the stomach58/201758/2017
malignant neoplasm of the thyroid gland58/201758/2017
malignant neoplasm of unknown primary site58/201758/2017
multiple sclerosis58/2017 
myelodysplastic syndrome58/201758/2017
neoplasm of the pituitary gland58/2017 
non-aneurysmal aortic atherosclerotic disease58/201758/2017
non-Hodgkin's lymphoma58/2017 
non-melanotic malignant neoplasm of the skin58/201758/2017
open-angle glaucoma58/201758/2017
optochiasmatic arachnoiditis58/201758/2017
otitis externa58/201758/2017
otitis media58/201758/2017
peritoneal adhesions58/201758/2017
renal artery atherosclerotic disease58/201758/2017
soft tissue sarcoma58/201758/2017
trigeminal neuropathy58/201758/2017
The above SOPs take effect from 18 September 2017.

Summary of Changes

  • Summary of Changes (PDF )

Finalised Declaration for:

ConditionDeclarationReasons for Decision
chemically-acquired brain injury caused by mefloquine, tafenoquine or primaquinePDF PDF Word

Completed Investigations

The above determinations and declarations conclude the previously advertised investigations into:

New Investigation

Decided to advertise the following investigation:
  • suicide and attempted suicide (focussed review - experiencing a category 2 stressor, and experiencing a problem with a long-term relationship)
The above declaration and investigation notice appear in the Government Notices Gazette of 29 August 2017.